Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 253

Sort by

Sort Order Select

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma.

Eve Blanquart, Rüçhan Ekren, Bineta Rigaud, Marie Veronique Joubert, virginie Baylot, Hélène Daunes, Marine Cuisinier, Marine Villard, Nadège Carrié, Celine Mazzotti, Liliana E Lucca, Aurore Perrot, Jill Corre, Thierry Walzer, Hervé Avet-Loiseau, Pierre-Paul Axisa, Ludovic Martinet

Blood blood.2023023529.

https://doi.org/10.1182/blood.2023023529

Published: 2024

Includes: Supplemental data

Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau

Blood (2024) 143 (20): 2029–2036.

https://doi.org/10.1182/blood.2023023597

Published: 2024

Includes: Supplemental data

Journal Articles

Smoldering multiple myeloma: taking the narrow over the wide path?

Herve Avet-Loiseau, Nizar J. Bahlis

Blood (2024) 143 (20): 2025–2028.

https://doi.org/10.1182/blood.2024023880

Published: 2024

Journal Articles

Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020

Blood (2023) 142 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2023-173845

Published: 2023

Journal Articles

French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma

Benjamin Hebraud, Miguel Granell, Leopoldine Lapierre, Pierre Luc Mouchel, Guillaume Beziat, Nina Sicard, Maeva Bonneau, Jules Higue, Florence Sougy, Sophie Perriat, Charlotte Morel, Pierre Bories, Jill Corre, Herve Avet Loiseau, Christian Recher, Aurore Perrot

Blood (2023) 142 (Supplement 1): 4736.

https://doi.org/10.1182/blood-2023-179727

Published: 2023

Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Blood (2023) 142 (Supplement 1): 6741.

https://doi.org/10.1182/blood-2023-185699

Published: 2023

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Blood (2023) 142 (Supplement 1): 6724.

https://doi.org/10.1182/blood-2023-186599

Published: 2023

Journal Articles

Single Cell Multi-Omic Correlation of Single Nucleotide Variants, Copy Number Variation and Surface Epitopes for Clonal Profiling of Myeloma

Adam Sciambi, Cedric Dos Santos, Yang Li, Joanne Bio Nguyen, Priyam Priyam, Vivek Chopra, Habib Hamidi, Michael Nixon, Yann Nouet, Todd E. Druley, Herve Avet-Loiseau

Blood (2023) 142 (Supplement 1): 4714.

https://doi.org/10.1182/blood-2023-189518

Published: 2023

Journal Articles

Potential future direction of measurable residual disease evaluation in multiple myeloma

Mohamad Mohty, Hervé Avet-Loiseau, Florent Malard, Jean-Luc Harousseau

Blood (2023) 142 (18): 1509–1517.

https://doi.org/10.1182/blood.2023020284

Published: 2023

Includes: Supplemental data

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Blood (2023) 142 (Supplement 1): 6742.

https://doi.org/10.1182/blood-2023-185792

Published: 2023

Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau

Blood (2023) 142 (Supplement 1): 207.

https://doi.org/10.1182/blood-2023-174044

Published: 2023

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Blood (2023) 141 (11): 1308–1315.

https://doi.org/10.1182/blood.2022017863

Published: 2023

Includes: Supplemental data

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

MRD in multiple myeloma: does CR really matter?

Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau

Blood (2022) 140 (23): 2423–2428.

https://doi.org/10.1182/blood.2022016170

Published: 2022

Journal Articles

Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable MM

Mehmet K. Samur, Jill Corre, Luka Pavageau, Laure Buisson, Nikhil C Munshi, Herve Avet-Loiseau

Blood (2022) 140 (Supplement 1): 1544–1545.

https://doi.org/10.1182/blood-2022-168807

Published: 2022

NARROW

RAS/RAF landscape in monoclonal plasma cell conditions

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in Multiple Myeloma.

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Smoldering multiple myeloma: taking the narrow over the wide path?

Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020

French Monocentric Experience of Outpatient Step-up Dosing of Teclistamab in Relapsed Refractory Multiple Myeloma

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Single Cell Multi-Omic Correlation of Single Nucleotide Variants, Copy Number Variation and Surface Epitopes for Clonal Profiling of Myeloma

Potential future direction of measurable residual disease evaluation in multiple myeloma

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

MRD in multiple myeloma: does CR really matter?

Intergenic Non-Switch Immunoglobulin Translocations Are Frequently Observed in Genomically Unstable MM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only